Eyedeal holds National Key R&D Program key special project launch and biomedical technology industrialization development forum in Xi’an

On October 13, Xi’an Eyedeal’s National Key R&D Program event was hosted by the China Biotechnology Development Center, China Medical Device Industry Association, and Xi’an High-tech Zone Management Committee.
At the meeting, Professor Wei Yuquan, academician of the Chinese Academy of Sciences and director of the State Key Laboratory of Biotherapy of Sichuan University, delivered a keynote speech.
Nie Zhongqiu, member of the Standing Committee of the Xi’an Municipal Party Committee and deputy mayor, and Professor Xi Tingfei, leader of the key special expert group of Biomedical Material Research and Development and Tissue Organ Repair and Replacement also spoke.
In respective speeches, Lu Shan, the representative of the China Biotechnology Development Center, shared the National Key R&D Plan project mission statement with the person in charge of the Xi’an Eyedeal project.
Yang Renhua, Director of the Management Committee of Xi’an High-tech Zone, presided over the kick-off meeting and forum activities.
At the subsequent biomedical technology industrialization development forum, Qu Jia, Lu Fan, Sun Xinghuai, and Ge Jian respectively delivered insightful speeches on topics such as ophthalmology theoretical research, technology transformation and application, industrialization trends, and market expectations.
More than 30 well-known medical experts and scholars from across the country and more than 10 renowned experts in Shaanxi attended the kick-off meeting and forum activities.

Professor Wei Yuquan, academician of the Chinese Academy of Sciences and director of the State Key Laboratory of Biotherapy of Sichuan University, said, “When talking about translational medicine, enterprises and R&D institutions must closely cooperate in project development and technical support. The most difficult thing now is that there are few promising projects. Entrepreneurs cannot find good projects in the country regardless of money. Intraocular lenses are urgently needed here, yet there are no high-end intraocular lens products in China.”
He stated his belief that the Xi’an Eyedeal project is very meaningful, has large market potential and is a worthy endeavor.
“When developing deep technology applications we must pay attention to manufacturing processes, the high level of technology required, and attracting talented professionals able to create and transform.

Member of the Standing Committee of the Xi’an Municipal Party Committee and Deputy Mayor Nie Zhongqiu congratulated the successful inclusion of the Xian Eyedeal intraocular lens project in the National Key R&D Program.
He said, “Being included in the National Key R&D Program is a lofty honor for enterprises, and for the government. It is also a strong affirmation of Xi’an’s level of support for high-tech industries and scientific research projects. It is believed that as long as Xi’an Eyedeal continues to exert its technological advantages and accelerate the transformation of scientific and technological achievements, the Eyedeal intraocular lens project will be launched to the market faster and create huge economic value and social benefits.
“Today’s Xi’an is a new and innovative city integrating fashion and modernity, and is the leader in the northwest. In the process of accelerating the construction of an international metropolis with historical and cultural characteristics, Xi’an will definitely implement the central government’s vision of entrepreneurs growing in a healthy environment, promoting the requirements of excellent entrepreneurial spirit, always upholding and emphasizing business, pro-business, safe business, and service business, and striving to create a first-class service environment to help enterprises accelerate development in Xi’an as it continues to grow bigger and stronger.”

Professor Qu Jia, Director of National Eye Optometry Engineering Technology Research Center, Dean of the Ophthalmology Hospital Affiliated to Wenzhou Medical University Director of the State Key Laboratory of Optometry and Visual Science.

Professor Lu Fan, President of Wenzhou Medical University.

Professor Sun Xinghuai, Dean of the Eye, Ear, Nose and Throat Hospital of Fudan University.

Professor Ge Jian, former director of the State Key Laboratory of Ophthalmology and former director of Zhongshan Ophthalmology Center, Sun Yat-sen University.
Professor Ge Jian also said, “If the latest generation of intraocular lenses of Xi’an Eyedeal are put into production, patient treatment costs will definitely be high. However, because it uses cross-linked polyolefin materials, the product quality will be better than foreign products, and it will become the first choice for eye patients. Now the company has a team of high-level talents, high-tech equipment and production lines, and hopes to complete clinical verification, mass production and market launch as soon as possible.”

Biomedical Material R&D and Tissue Organ Repair and Replacement key expert group leader Professor Xi Tingfei, Peking University

Yang Renhua, Director of the Management Committee of Xi’an High-tech Zone

The Application of high-tech biomedical materials to develop a new generation of ocular intraocular lens products included in the National Key Research and Development Program is led by Xi’an Eyedeal Medical Technology Co., Ltd., Wenzhou Medical University, Air Force Military Medical University The Fourth Military Medical University), Peking University People’s Hospital and the Institute of Computing Technology of the Chinese Academy of Sciences participated in the event.
Xi’an Eyedeal Medical Technology Co., Ltd. was established in 2015. The company uses independent intellectual property rights and patents to develop and produce intraocular lens products. Its technology is currently the world’s most advanced for the treatment of cataracts. In the future, Xi’an Eyedeal will develop and produce a series of advanced optical intraocular lenses and adjustable intraocular lenses based on implantable medical devices, with intraocular lenses as the core, and using the world’s most advanced materials and equipment technology. After this project is put into production, it will increase annual fiscal revenue by more than 1.2 billion yuan for the country and local governments. In line with its mission of “bringing high-quality, innovative medical products to every patient that needs them”, Xi’an Eyedeal will strive to become an innovative multinational enterprise integrating raw material production, product development and production.
News link: In theory, there are currently 14 million patients needing cataract surgery in China every year. A large number of patients cannot receive surgery due to economic reasons. In fact, the current volume of cataract surgery in my country is only about 1.5 million, which is far below the level of Europe, America, and even India. Therefore it is necessary to speed up research and development of the core technology of intraocular lens products, increase its localization rate, and reduce the cost of surgery.
Intraocular lens implantation surgery is currently the only efficacious treatment for senile cataract. It has good clinical results. However existing intraocular lenses still have unresolved challenges affecting clinical outcomes.
Problems include micro-bubbles inside the intraocular lens causing postoperative lens flash and leukoplakia. Small intraocular lens optical surfaces may also cause postoperative glare and halo effects. Intraocular lenses cn result in high chromatic aberration. And intraocular lens implantation can lead to chronic inflammation and further cataract development.
These problems are inseparable from the material properties of the intraocular lens. For decades, scientists have been exploring new biological materials and improving design and production process to enhance the performance of intraocular lenses. However, the existing problems need to be solved urgently. In recent years, the rise of personalized medicine and bionics hase seen clinicians eager to obtain higher curative intraocular lenses, such as adjustable intraocular lenses closer to the human physiology, to further improve the curative effect. It is imperative to develop a new generation of intraocular lenses using new materials.
At present, the materials used to manufacture intraocular lenses include hydrophilic acrylic materials, silicone gels, hydrogels, and polymethyl methacrylate. Hydrophobic acrylic materials are currently most preferred. Intraocular lens products, especially high-end intraocular lens products, are almost exclusively produced by brands such as Alcon and Bausch & Lomb.
Lack of high-end domestic medical equipment is common in China. Combining the trends of communitization and aging, the research and development of high-end new domestic medical devices is a major direction for the development of China’s medical device industry. Compared with high-speed rail, automobiles, household appliances and other fields with a high localization rate, the R&D and localization of medical devices urgently needs more support, investment and attention.